Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study (ClinicalTrials.gov NCT03761056) we evaluated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Neelapu, Sattva S., Dickinson, Michael, Munoz, Javier, Ulrickson, Matthew L., Thieblemont, Catherine, Oluwole, Olalekan O., Herrera, Alex F., Ujjani, Chaitra S., Lin, Yi, Riedell, Peter A., Kekre, Natasha, de Vos, Sven, Lui, Christine, Milletti, Francesca, Dong, Jinghui, Xu, Hairong, Chavez, Julio C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018426/
https://www.ncbi.nlm.nih.gov/pubmed/35314842
http://dx.doi.org/10.1038/s41591-022-01731-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018426/
https://www.ncbi.nlm.nih.gov/pubmed/35314842
http://dx.doi.org/10.1038/s41591-022-01731-4

Ejemplares similares